Michael S. Rafii

Michael S. Rafii

Auto-generated profile, based on publicly available information

Michael S. Rafii

Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MRMichael S. Rafii
Michael S. Rafii
RSReisa A. Sperling
Reisa A. Sperling
MDMichael C. Donohue
Michael C. Donohue
JZJin Zhou
Jin Zhou
CRClaire Roberts
Claire Roberts
PAPaul S. Aisen
Paul S. Aisen
Introduction: The Alzheimer's disease (AD) continuum begins with a long asymptomatic or preclinical stage, during which amyloid beta (Aβ) is accumulating for more than a decade prior to widespread cortical tauopathy, neurodegeneration, and manifestation of clinical symptoms. The AHEAD 3‐45 Study (BAN2401‐G000‐303) is testing whether intervention with lecanemab (BAN2401), a humanized immunoglobulin 1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ, initiated during this asymptomatic stage can slow biomarker changes and/or cognitive decline. The AHEAD 3‐45 Study is conducted as a Public‐Private Partnership of the Alzheimer's Clinical Trial Consortium (ACTC), funded by the National Institute on Aging, National Institutes of Health (NIH), and Eisai Inc.Methods: The AHEAD 3‐45 Study was launched on July 14, 2020, and consists of two sister trials (A3 and A45) in cognitively unimpaired (CU) individuals ages 55 to 80 with specific dosing regimens tailored to baseline brain amyloid levels on screening positron emission tomography (PET) scans: intermediate amyloid (≈20 to 40 Centiloids) for A3 and elevated amyloid (>40 Centiloids) for A45. Both trials are being conducted under a single protocol, with a shared screening process and common schedule of assessments. A3 is a Phase 2 trial with PET‐imaging end points, whereas A45 is a Phase 3 trial with a cognitive composite primary end point. The treatment period is 4 years. The study utilizes innovative approaches to enriching the sample with individuals who have elevated brain amyloid. These include recruiting from the Trial‐Ready Cohort for Preclinical and Prodromal Alzheimer's disease (TRC‐PAD), the Australian Dementia Network (ADNeT) Registry, and the Japanese Trial Ready Cohort (J‐TRC), as well as incorporation of plasma screening with the C2N mass spectrometry platform to quantitate the Aβ 42/40 ratio (Aβ 42/40), which has been shown previously to reliably identify cognitively normal participants not likely to have elevated brain amyloid levels. A blood sample collected at a brief first visit is utilized to "screen out" individuals who are less likely to have elevated brain amyloid, and to determine the participant's eligibility to proceed to PET imaging. Eligibility to randomize into the A3 Trial or A45 Trial is based on the screening PET imaging results.Result: The focus of this article is on the innovative design of the study.Discussion: The AHEAD 3‐45 Study will test whether with lecanemab (BAN2401) can slow the accumulation of tau and prevent the cognitive decline associated with AD during its preclinical stage. It is specifically targeting both the preclinical and the early preclinical (intermediate amyloid) stages of AD and is the first secondary prevention trial to employ plasma‐based biomarkers to accelerate the screening process and potentially substantially reduce the number of screening PET scans.

28 June 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CJClifford R. Jack
Clifford R. Jack
SAScott J. Andrews
Scott J. Andrews
TBThomas G. Beach
Thomas G. Beach
TBTeresa Buracchio
Teresa Buracchio
BDBilly Dunn
Billy Dunn
MCMaria C. Carrillo
Maria C. Carrillo

18 May 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
MRMichael S. Rafii
Michael S. Rafii
PAPaul S. Aisen
Paul S. Aisen

18 September 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
MRMichael S. Rafii
Michael S. Rafii
ALAna S. Lukic
Ana S. Lukic
RARandolph D. Andrews
Randolph D. Andrews
JBJames Brewer
James Brewer
RRRobert A. Rissman
Robert A. Rissman
FIFor The Down Syndrome Biomarker Initiative And The Alzheimer’S Disease Neuroimaging Initiative
For The Down Syndrome Biomarker Initiative And The Alzheimer’S Disease Neuroimaging Initiative
Background: Adults with Down syndrome (DS) represent an enriched population for the development of Alzheimer’s disease (AD), which could aid the study of therapeutic interventions, and in turn, could benefit from discoveries made in other AD populations. Objectives: 1) Understand the relationship between tau pathology and age, amyloid deposition, neurodegeneration (MRI and FDG PET), and cognitive and functional performance; 2) detect and differentiate AD-specific changes from DS-specific brain changes in longitudinal MRI. Methods: Twelve non-demented adults, ages 30 to 60, with DS were enrolled in the Down Syndrome Biomarker Initiative (DSBI), a 3-year, observational, cohort study to demonstrate the feasibility of conducting AD intervention/prevention trials in adults with DS. We collected imaging data with 18 F-AV-1451 tau PET, AV-45 amyloid PET, FDG PET, and volumetric MRI, as well as cognitive and functional measures and additional laboratory measures. Results: All amyloid negative subjects imaged were tau-negative. Among the amyloid positive subjects, three had tau in regions associated with Braak stage VI, two at stage V, and one at stage II. Amyloid and tau burden correlated with age. The MRI analysis produced two distinct volumetric patterns. The first differentiated DS from normal (NL) and AD, did not correlate with age or amyloid, and was longitudinally stable. The second pattern reflected AD-like atrophy and differentiated NL from AD. Tau PET and MRI atrophy correlated with several cognitive and functional measures. Conclusions: Tau accumulation is associated with amyloid positivity and age, as well as with progressive neurodegeneration measurable using FDG and MRI. Tau correlates with cognitive decline, as do AD-specific hypometabolism and atrophy.

14 September 2015 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
MRMichael S. Rafii
Michael S. Rafii
HWHannah Wishnek
Hannah Wishnek
JBJames B. Brewer
James B. Brewer
MDMichael C. Donohue
Michael C. Donohue
SNSeth Ness
Seth Ness
RRRobert A. Rissman
Robert A. Rissman
To gain further knowledge on the preclinical phase of AD, we sought to characterize cognitive performance, volumetric MRI, amyloid PET, FDG PET, retinal amyloid, and plasma biomarkers in a cohort of non-demented adults with Down Syndrome (DS). The goal of the Down Syndrome Biomarker Initiative (DSBI) pilot is to test feasibility of this approach for future multicenter studies. We enrolled 12 non-demented participants with DS between the ages of 30-60 years old. Participants underwent extensive cognitive testing, volumetric MRI, amyloid PET 18F-florbetapir, 18F-fluorodeoxyglucose (18F-FDG) PET, and retinal amyloid imaging. In addition, plasma beta-amyloid species were measured and ApoE genotyping was performed. Consistent with previous autopsy studies, subjects demonstrated amyloid PET positivity reflecting fibrillar amyloid plaque deposition. Results from our multimodal analysis also suggest greater hippocampal atrophy with amyloid load. Additionally, we identified an inverse relationship between amyloid load and regional glucose metabolism. Cognitive and functional measures did not correlate with amyloid load in DS but did correlate with regional FDG PET measures. Retinal amyloid imaging demonstrated presence of plaques. Biomarkers of AD can be readily studied in adults with DS as in other preclinical AD populations. Importantly, all subjects in this feasibility study were able to complete all test procedures. The data indicate that a large, multicenter longitudinal study is feasible to better understand the trajectories of AD biomarkers in this enriched population. This trial is registered with ClinicalTrials.gov, number NCT02141971.

12 September 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JSJonathan Santoro
Jonathan Santoro
DPDania Pagarkar
Dania Pagarkar
DCDuong T. Chu
Duong T. Chu
MRMattia Rosso
Mattia Rosso
KPKelli C. Paulsen
Kelli C. Paulsen
MRMichael S. Rafii
Michael S. Rafii